Nivolumab-Induced Lichenoid Eruption: A Case Report

Prior research has shown that immune checkpoint inhibitors like nivolumab have transformed the prognosis for patients with advanced malignancies by blocking the programmed death-1 receptor. These therapeutic agents prevent the suppression of T-cell activity, thereby enabling the immune system to recognize and eliminate malignant cells more effectively. However, this heightened immune state frequently results in off-target effects known as immune-related adverse events that can damage healthy tissues. Cutaneous toxicities represent the most frequent category of these side effects, often appearing as maculopapular rashes, pruritus, or more complex inflammatory conditions. Lichenoid eruptions are a specific morphological variant of these skin reactions that mimic the clinical and histological features of lichen planus. While many skin reactions are mild, some progress to a severity that threatens the continuity of the primary oncological treatment plan. This absence of evidence motivated the documentation of successful therapeutic interventions that permit the maintenance of primary oncological protocols.

This case report details the clinical progression and therapeutic resolution of a severe skin reaction in a patient treated for metastatic desmoplastic melanoma. The investigation focuses on identifying the specific morphological characteristics of the pruritic violaceous papules that emerged during the course of nivolumab therapy. Researchers aimed to validate the use of histopathology as a definitive tool for diagnosing lichenoid interface dermatitis in the context of immunotherapy. A primary goal of the study was to demonstrate a multi-tiered pharmacological approach that combines topical, intralesional, and systemic medications. The study evaluates whether this aggressive dermatological management can sufficiently control symptoms to avoid the premature termination of the checkpoint inhibitor regimen. By documenting this specific case, the authors provide a clinical roadmap for managing complex cutaneous toxicities without sacrificing cancer treatment efficacy. The report serves to bridge the gap between oncological necessity and dermatological safety in the management of advanced melanoma.

The medical team monitored a patient with metastatic desmoplastic melanoma who received regular infusions of the programmed death-1 inhibitor nivolumab. Clinical assessment occurred five months after the start of treatment when the patient presented with widespread pruritic violaceous papules and plaques. To confirm the underlying pathology, the clinicians performed a skin biopsy for detailed histopathological evaluation of the affected tissue. The diagnostic process specifically looked for signs of lichenoid interface dermatitis, characterized by a band-like inflammatory infiltrate at the dermo-epidermal junction. Management of the condition involved the application of high-potency clobetasol ointment and the administration of intralesional corticosteroids into the most recalcitrant plaques. Systemic intervention included a regimen of low-dose oral prednisolone and the oral retinoid acitretin to modulate the systemic immune response. The patient continued the nivolumab infusions throughout this dermatological treatment period, completing a full twelve-month course of immunotherapy.

The patient successfully completed one year of nivolumab therapy for metastatic desmoplastic melanoma despite the development of a significant lichenoid eruption. Clinical observations five months into the treatment revealed the sudden onset of pruritic violaceous papules and plaques across the body. Histopathological analysis of the biopsy samples confirmed the presence of lichenoid interface dermatitis, a hallmark of certain immune-related adverse events. The combination of clobetasol ointment and intralesional corticosteroids provided rapid localized improvement of the symptomatic skin lesions. Adding low-dose oral prednisolone and acitretin to the treatment plan effectively managed the widespread inflammation and prevented the further spread of the eruption. These interventions allowed the patient to maintain the immunotherapy schedule without any interruptions or dose reductions for the remainder of the year. The final assessment showed that the cutaneous symptoms were well-controlled, supporting the decision to continue the primary oncological intervention.

Nivolumab-induced lichenoid eruptions can be managed effectively through a coordinated dermatological strategy that utilizes both topical and systemic pharmacological agents. This case highlights that the emergence of lichenoid interface dermatitis does not necessitate the immediate cessation of programmed death-1 inhibitor therapy. Utilizing steroid-sparing agents like acitretin alongside low-dose prednisolone offers a viable method for controlling skin toxicity while preserving anti-tumor immunity. The successful completion of a one-year treatment course for metastatic desmoplastic melanoma underscores the importance of interdisciplinary care in oncology. These findings suggest that aggressive management of cutaneous immune-related adverse events can optimize the delivery of life-saving cancer treatments. Future clinical guidelines should incorporate multi-modal dermatological protocols to assist clinicians in navigating these common yet challenging side effects. The study reinforces the role of onco-dermatology in improving patient adherence and outcomes in the era of modern immunotherapy.